Figure 3: Combination therapy with SVF and Ad-COMP-Ang1 gene induces cavernous endothelial cell proliferation in STZ-induced diabetic mice. (a) CD31 (green) and phosphohistone H3 (PH3; red) staining in cavernous tissue from age-matched control mice (C) group and STZ-induced diabetic mice stimulated at 4 weeks after intracavernous injection of PBS (P, 20 μl), ad-LacZ (L, 2 × 108 particles per 20 μl), SVF (S, 1 × 105 cells per 20 μl), Ad-COMP-Ang1 (CA, 2 × 108 particles per 20 μl), or combination (S + CA). Nuclei were labeled with DAPI (blue). Scale bars = 50 μm. (b) Number of PH 3-immunopositive endothelial cells per HPF. Each bar depicts the mean value ± standard deviation from n = 5 animals per group. *P < 0.01, P or L versus C group. #P < 0.01, S or CA versus P or L groups. †P < 0.01, S + CA versus S or CA groups. The P values were determined by one-way ANOVA. Ad-COMP-Ang1: adenovirus-mediated cartilage oligomeric matrix angiopoietin-1; DAPI: 4',6-diamidino-2-phenylindole; HPF: high-power field; PBS: phosphate-buffered saline; STZ: streptozotocin; SVF: stromal vascular fraction.